Drug patch approved for treatment of depression

Published: 3-Mar-2006

Somerset Pharmaceuticals' Emsam (selegiline) has become the first skin (transdermal) patch to gain US Food and Drug Administration (FDA) approval for the treatment of major depression.


Somerset Pharmaceuticals' Emsam (selegiline) has become the first skin (transdermal) patch to gain US Food and Drug Administration (FDA) approval for the treatment of major depression.

See more

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

Read more
The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials

Trending Articles

  1. New UK-developed blood test identifies breast cancer type without biopsy A new ctDNA-based blood test offers near-90% accuracy in identifying and tracking breast cancer subtypes, opening opportunities for earlier treatment matching and more efficient therapy selection
  2. New Osaka-developed reverse genetics system accelerates norovirus vaccine and drug research Osaka University scientists have created the first simple, efficient system to generate infectious human noroviruses, paving the way for faster antiviral screening and vaccine development
  3. GlaxoSmithKline and Oxford BioTherapeutics partner to advance antibody-based therapeutics for cancer The collaboration leverages OBT's proprietary OGAP-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targets
  4. PLL Therapeutics opens New Zealand subsidiary to accelerate ALS clinical research in Asia-Pacific The new entity will support Phase II ALS patient recruitment in New Zealand (where incidence rates exceed the global average) and expand PLL Therapeutics’ footprint in the Asia-Pacific neurodegenerative disease research landscape
  5. Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Lindus Health and Quotient Sciences team up to accelerate drug development process

The pair will provide biotech and pharma sponsors with enhanced patient recruitment for early-stage clinical trials and a direct path from first-in-human to proof-of-concept trials
Manufacturing

Cellevate achieves ISO 9001:2015 certification alongside GMP production processes in new cleanroom

The certification caps off a strong 2025 for the company, which now has a scalable foundation for expanding manufacturing capacity and implementing GMP-ready processes for commercial volumes
Drug Delivery

Zephyrus Innovations receives 510(k) clearance from FDA for VaporShield CSTD

With CSTDs now required in the US under USP<800> legislation, VaporShield is the first direct injection CSTD for subcutaneous and intramuscular administration
Manufacturing

LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener

Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
Dosage Forms

AI-engineered nasal spray could block flu and COVID-19

Researchers have successfully developed an intranasal antiviral platform using AI technology to overcome the existing limitations of interferon-lambda treatments, revealing a possible universal prevention platform for multiple respiratory viruses
Research & Development

CAR T-cell therapy shows promise for restoring gut health and intestinal regeneration

Researchers at Cold Spring Harbor Laboratory have demonstrated that anti-uPAR CAR T-cell therapy can clear senescent cells and restore intestinal regeneration, offering a potential new approach to treating age- and radiation-related gut damage
Cell & Gene Therapy

Leucid Bio and Syenex team up for in vivo CAR-T cell engineering

The pair will harness Syenex’s VivoCell Platform to precisely deliver Leucid’s CAR-T asset LEU011 construct to T-cells in vivo, representing a next-generation approach and moving toward a simpler, possibly off-the-shelf administration route
Subscribe now